Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)